Pharmaceuticals - Estonia

Estonia

The Pharmaceuticals market in Estonia is expected to reach a revenue of US$265.60m in 2024.
The largest market within this industry is Oncology Drugs, which is projected to have a market volume of US$46.77m in the same year.
Over the period of 2024-2029, the market is anticipated to grow at an annual growth rate of 4.77%, resulting in a market volume of US$335.30m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$630.30bn in 2024.
Estonia's pharmaceutical market is experiencing a surge in digital health solutions, with a focus on e-prescriptions and telemedicine services.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Estonia has been growing steadily in recent years.

Customer preferences: Estonian customers are becoming increasingly health-conscious and are seeking out more natural and holistic remedies. This has led to a rise in demand for herbal and homeopathic medicines, as well as supplements and vitamins. However, traditional pharmaceuticals still dominate the market, particularly in the treatment of chronic illnesses.

Trends in the market: One of the main trends in the Estonian Pharmaceuticals market is the increasing use of e-prescriptions. This has made it easier for patients to obtain their medications and has also helped to reduce errors and improve efficiency in the healthcare system. Another trend is the growing importance of generic drugs, which are becoming more widely available and affordable. This has put pressure on brand-name drug manufacturers to lower their prices and has increased competition in the market.

Local special circumstances: Estonia has a relatively small population, which means that the market for Pharmaceuticals is also relatively small. This has made it difficult for international pharmaceutical companies to justify investing in the country, which has in turn led to a greater reliance on domestic producers. Additionally, the Estonian government heavily regulates the Pharmaceuticals market, which can make it challenging for companies to enter the market or introduce new products.

Underlying macroeconomic factors: Estonia has a strong economy and a well-developed healthcare system, which has helped to support growth in the Pharmaceuticals market. However, the country also faces challenges such as an aging population and a high prevalence of chronic diseases, which could put pressure on the healthcare system in the future. Additionally, Estonia's membership in the European Union has helped to facilitate trade and investment in the Pharmaceuticals market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.